SARS-CoV-2-IN-15
SARS-CoV-2-IN-15 (compound 11) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.49 μM. SARS-CoV-2-IN-15 is a niclosamide analogue. SARS-CoV-2-IN-15 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally[1].
Product Specifications
CAS Number
1580-42-3
UNSPSC
12352005
Hazard Statement
H315, H320, H335
Target
SARS-CoV
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/sars-cov-2-in-15.html
Purity
99.65
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
O=C(NC1=CC=CC(C(F)(F)F)=C1)C2=CC(Cl)=CC=C2O
Molecular Formula
C14H9ClF3NO2
Molecular Weight
315.67
Precautions
H315, H320, H335
References & Citations
[1] Juang YP, et al. Design, synthesis and biological evaluations of niclosamide analogues against SARS-CoV-2. Eur J Med Chem. 2022 May 5;235:114295.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
EphA7 (Ephrin Type-A Receptor 7, EPH Homology Kinase 3, EHK-3, EPH-like Kinase 11, EK11, hEK11, EHK3, HEK11) (PE) discontinued
Phospho-TGF beta Receptor II (Tyr259) Polyclonal Antibody, PerCP Conjugated
